Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy

作     者：Yusuf A.Rajabally 

作者机构：Regional Neuromuscular Clinic Queen Elizabeth Hospital University Hospitals of Birmingham 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2015年第10卷第9期

页      面：1399-1400页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

基　　金：CSL Behring  LfB France and Baxter 

主　　题：CIDP Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy oral 

摘      要：Chronic inflammatory demyelinating polyneuropathy （CIDP） is a treatable immune-mediated disorder, which causes in its typical form, symmetric proximal and distal weakness with large fibre sensory impairment involving the four limbs. There are currently three main first-line therapeutic options for CIDP. These consist of corticosteroids, immunoglobulins and plasma exchanges （PE） which have all been found effective in a number of trials conducted over the past several years （Van den Bergh and Rajabally, 2013）. No immunosuppressant therapy has shown benefit in CIDP, although they are utilized by many clinicians in various circumstances despite absence of an evidence base.